Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer.
More than 1,500 people a year with an aggressive form of stomach cancer are set to receive a new treatment available on the NHS from today, after NICE recommended durvalumab - the first immunotherapy for people with this form of cancer.
Durvalumab, also known as Imfinzi and made by AstraZeneca, is recommended for adults whose stomach (gastric and gastro-oesophageal junction) cancer has not spread extensively and can be removed through surgery.
